USI’s proprietary pharmacy contract analysis tool identifies opportunities for a 20% - 30% reduction in pharmacy expenses, or 5% - 7.5% of total plan costs, compared to an unmanaged pharmacy contract.

We’ve estimated the financial impact for you. Feel free to update the assumptions. 

  • Total overall benefit plan savings of 5% to 7.5%
  • Up to 100% of drug manufacturer rebates are paid to the employer
  • Regular review of formulary options to reduce inclusion of drugs for the purpose of inflating PBM profit
  • Price negotiation via contract review can be accomplished with no impact to plan members

Typically, contract negotiations with incumbent PBMs yield opportunities for savings of 10-15%. 

Opportunities for an additional 10-15% reduction of costs are usually identified within the full procurement process.

It depends on your organization’s savings goals. USI’s proprietary tool assesses the financial impact of a change from your current pharmacy benefit contract’s terms and conditions to those of a top-quartile performing contract. In order to achieve maximum savings, a change in pharmacy provider may be required.

USI’s Pharmacy Contract Analysis is available to USI clients at no additional cost.

USI has a wide range of tools and solutions designed to impact overall costs.

One example: Additional savings can be made available by properly aligning incentives in your plan design, with limited impact to members.